ReWalk Exoskeleton Gains Aetna Coverage, Now Accessible Through Three Major Medicare Advantage Plans

GlobeNewswire Inc.GlobeNewswire Inc.
|||1 min read
Key Takeaway

Aetna approves Medicare Advantage coverage for ReWalk exoskeleton, expanding access to three major insurers serving 16 million beneficiaries and marking progress for wearable robotic technology reimbursement.

ReWalk Exoskeleton Gains Aetna Coverage, Now Accessible Through Three Major Medicare Advantage Plans

Lifeward announced that Aetna has approved Medicare Advantage coverage for its ReWalk Personal Exoskeleton, marking a significant expansion of insurer support for the FDA-approved wearable technology. The approval brings the total number of major Medicare Advantage carriers covering the device to three, alongside existing coverage from Humana and UnitedHealthcare.

The three insurers collectively serve approximately 16 million Medicare Advantage beneficiaries, substantially broadening patient access to the exoskeleton system designed for individuals with spinal cord injuries. This expanded coverage represents a key milestone for reimbursement of wearable robotic technology within the Medicare Advantage market, historically a challenge for emerging medical devices seeking mainstream adoption.

The addition of Aetna coverage reflects growing recognition of the ReWalk system's clinical value and potential to improve mobility and quality of life for eligible patients. The sequential approvals across multiple major carriers suggest potential for continued expansion of coverage policies within the Medicare Advantage landscape.

Source: GlobeNewswire Inc.

Back to newsPublished Feb 17

Related Coverage

Benzinga

Aethlon Medical Advances Hemopurifier Trial to Final Cohort After Safety Clearance

Aethlon Medical's Hemopurifier device advances to final clinical trial phase following positive safety review with no adverse events reported.

AEMD
The Motley Fool

Pharma Giant and Healthcare Insurer Offer Entry Points for Long-Term Investors

Pfizer and UnitedHealth Group present buying opportunities for $500 investors. Pfizer trades at 9x forward earnings with oncology growth plans; UnitedHealth at 15x after cost-cutting initiatives.

PFEUNH
GlobeNewswire Inc.

Mesoblast Plans First R&D Day to Showcase Pipeline, New Cell Therapy Tech

Mesoblast Limited will host inaugural R&D Day April 8, 2026 in NYC, featuring Ryoncil commercialization updates and new cellular medicine technology.

MESO
Investing.com

Defensive Sectors Flash Mixed Signals as Volatility Spikes

Defensive sectors show conflicting technical signals: Utilities strengthen while Consumer Staples weaken and Health Care forms bearish patterns, creating mixed market outlook.

JNJWMTNVDA
Benzinga

LENSAR Terminates Alcon Merger After FTC Opposition, Retains $10M Deposit

LENSAR ends merger with Alcon due to FTC regulatory hurdles. Company retains $10M deposit, refocuses on independent growth strategy for robotic cataract laser system.

LNSR
GlobeNewswire Inc.

Global Dental Insurance Market Set to Surge 67% by 2032, Reaching $198B

Global dental insurance market projected to grow 67% from $118.77B (2026) to $198.31B (2032), driven by digital transformation, value-based care models, and regulatory shifts.

UNHHUMCI